Revisión
Efectos adversos cutáneos del imatinib (inhibidor de la tirosín cinasa)
Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor
Leído
32136
Vecesse ha leído el artículo
6461
Total PDF
25675
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 129 | 14 | 143 |
| 2025 5 | 758 | 74 | 832 |
| 2025 4 | 784 | 53 | 837 |
| 2025 3 | 808 | 65 | 873 |
| 2025 2 | 783 | 77 | 860 |
| 2025 1 | 659 | 59 | 718 |
| 2024 12 | 574 | 72 | 646 |
| 2024 11 | 518 | 113 | 631 |
| 2024 10 | 612 | 90 | 702 |
| 2024 9 | 575 | 83 | 658 |
| 2024 8 | 596 | 105 | 701 |
| 2024 7 | 604 | 91 | 695 |
| 2024 6 | 548 | 80 | 628 |
| 2024 5 | 609 | 89 | 698 |
| 2024 4 | 616 | 68 | 684 |
| 2024 3 | 599 | 64 | 663 |
| 2024 2 | 666 | 69 | 735 |
| 2024 1 | 621 | 69 | 690 |
| 2023 12 | 630 | 45 | 675 |
| 2023 11 | 469 | 63 | 532 |
| 2023 10 | 496 | 59 | 555 |
| 2023 9 | 487 | 60 | 547 |
| 2023 8 | 495 | 49 | 544 |
| 2023 7 | 407 | 64 | 471 |
| 2023 6 | 353 | 46 | 399 |
| 2023 5 | 321 | 73 | 394 |
| 2023 4 | 365 | 58 | 423 |
| 2023 3 | 353 | 76 | 429 |
| 2023 2 | 236 | 40 | 276 |
| 2022 1 | 303 | 54 | 357 |
| 2022 12 | 243 | 55 | 298 |
| 2022 11 | 274 | 78 | 352 |
| 2022 10 | 284 | 66 | 350 |
| 2022 9 | 224 | 106 | 330 |
| 2022 8 | 250 | 93 | 343 |
| 2022 7 | 266 | 103 | 369 |
| 2022 6 | 222 | 119 | 341 |
| 2022 5 | 217 | 58 | 275 |
| 2022 4 | 215 | 72 | 287 |
| 2022 3 | 210 | 122 | 332 |
| 2022 2 | 174 | 67 | 241 |
| 2021 1 | 241 | 82 | 323 |
| 2021 12 | 176 | 92 | 268 |
| 2021 11 | 182 | 87 | 269 |
| 2021 10 | 218 | 101 | 319 |
| 2021 9 | 196 | 83 | 279 |
| 2021 8 | 226 | 91 | 317 |
| 2021 7 | 210 | 114 | 324 |
| 2021 6 | 284 | 62 | 346 |
| 2021 5 | 180 | 78 | 258 |
| 2021 4 | 565 | 135 | 700 |
| 2021 3 | 322 | 70 | 392 |
| 2021 2 | 265 | 60 | 325 |
| 2020 1 | 238 | 75 | 313 |
| 2020 12 | 131 | 50 | 181 |
| 2020 11 | 124 | 38 | 162 |
| 2020 10 | 86 | 58 | 144 |
| 2020 9 | 73 | 29 | 102 |
| 2020 8 | 90 | 39 | 129 |
| 2020 7 | 138 | 32 | 170 |
| 2020 6 | 95 | 30 | 125 |
| 2020 5 | 75 | 30 | 105 |
| 2020 4 | 100 | 18 | 118 |
| 2020 3 | 72 | 34 | 106 |
| 2020 2 | 5 | 20 | 25 |
| 2020 1 | 4 | 22 | 26 |
| 2019 12 | 9 | 21 | 30 |
| 2019 11 | 7 | 21 | 28 |
| 2019 10 | 0 | 94 | 94 |
| 2019 9 | 10 | 41 | 51 |
| 2019 8 | 22 | 24 | 46 |
| 2019 7 | 5 | 33 | 38 |
| 2019 6 | 4 | 25 | 29 |
| 2019 5 | 7 | 40 | 47 |
| 2019 4 | 2 | 35 | 37 |
| 2019 3 | 11 | 24 | 35 |
| 2019 2 | 11 | 15 | 26 |
| 2019 1 | 1 | 11 | 12 |
| 2018 12 | 3 | 5 | 8 |
| 2018 11 | 4 | 13 | 17 |
| 2018 10 | 10 | 6 | 16 |
| 2018 9 | 8 | 24 | 32 |
| 2018 8 | 1 | 86 | 87 |
| 2018 7 | 2 | 52 | 54 |
| 2018 6 | 0 | 52 | 52 |
| 2018 5 | 1 | 43 | 44 |
| 2018 4 | 1 | 41 | 42 |
| 2018 3 | 11 | 38 | 49 |
| 2018 2 | 146 | 44 | 190 |
| 2018 1 | 148 | 27 | 175 |
| 2017 12 | 89 | 26 | 115 |
| 2017 11 | 86 | 58 | 144 |
| 2017 10 | 123 | 34 | 157 |
| 2017 9 | 72 | 63 | 135 |
| 2017 8 | 68 | 44 | 112 |
| 2017 7 | 97 | 42 | 139 |
| 2017 6 | 85 | 58 | 143 |
| 2017 5 | 89 | 31 | 120 |
| 2017 4 | 66 | 74 | 140 |
| 2017 3 | 96 | 68 | 164 |
| 2017 2 | 180 | 87 | 267 |
| 2016 1 | 82 | 24 | 106 |
| 2016 12 | 65 | 25 | 90 |
| 2016 11 | 97 | 36 | 133 |
| 2016 10 | 114 | 38 | 152 |
| 2016 9 | 182 | 49 | 231 |
| 2016 8 | 6 | 39 | 45 |
| 2016 7 | 11 | 31 | 42 |
| 2016 6 | 6 | 47 | 53 |
| 2016 5 | 4 | 3 | 7 |
| 2016 4 | 4 | 3 | 7 |
| 2016 3 | 5 | 2 | 7 |
| 2016 2 | 12 | 30 | 42 |
| 2015 1 | 12 | 1 | 13 |
| 2015 12 | 15 | 2 | 17 |
| 2015 11 | 10 | 4 | 14 |
| 2015 10 | 11 | 2 | 13 |
| 2015 9 | 3 | 29 | 32 |
| 2015 8 | 6 | 19 | 25 |
| 2015 7 | 126 | 18 | 144 |
| 2015 6 | 69 | 18 | 87 |
| 2015 5 | 56 | 10 | 66 |
| 2015 4 | 39 | 12 | 51 |
| 2015 3 | 79 | 7 | 86 |
| 2015 2 | 81 | 17 | 98 |
| 2015 1 | 52 | 15 | 67 |
| 2014 12 | 66 | 27 | 93 |
| 2014 11 | 49 | 10 | 59 |
| 2014 10 | 50 | 20 | 70 |
| 2014 9 | 39 | 32 | 71 |
Mostrar todo
